Sildenafil Improved Pulmonary Hypertension and Peripheral Blood Flow in a Patient with Scleroderma-Associated Lung Fibrosis and the Raynaud Phenomenon
- Stephan Rosenkranz;
- Frank Diet;
- Thomas Karasch;
- Julia Weihrauch;
- Klaus Wassermann; and
- Erland Erdmann
- From Klinik III für Innere Medizin and Klinik und Poliklinik für Dermatologie; Universität zu Köln.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Systemic scleroderma is a connective tissue disease involving several organ systems. Up to 90% of affected patients have the Raynaud phenomenon, and mortality rates largely depend on involvement of the lungs. In patients without pulmonary abnormalities, the 5-year survival rate is 90%, whereas in patients with systemic scleroderma–related pulmonary arterial …
This 100-word excerpt has been provided in the absence of an abstract.
Most Read
